Sutro Biopharma, Inc.

DB:S09 Stock Report

Market Cap: €198.8m

Sutro Biopharma Valuation

Is S09 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of S09 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate S09's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate S09's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for S09?

Key metric: As S09 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for S09. This is calculated by dividing S09's market cap by their current revenue.
What is S09's PS Ratio?
PS Ratio1.3x
SalesUS$160.96m
Market CapUS$206.97m

Price to Sales Ratio vs Peers

How does S09's PS Ratio compare to its peers?

The above table shows the PS ratio for S09 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.9x
HPHA Heidelberg Pharma
12x16.6%€102.1m
2INV 2invest
8.1xn/a€62.7m
FYB Formycon
14x33.4%€848.4m
BIO3 Biotest
1.5x3.6%€1.4b
S09 Sutro Biopharma
1.3x27.4%€207.0m

Price-To-Sales vs Peers: S09 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does S09's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.1x21.8%
S09 Sutro Biopharma
 1.3x27.4%US$206.97m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
S09 1.3xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.1x42.4%
S09 Sutro Biopharma
 1.3x-0.7%US$206.97m
No more companies

Price-To-Sales vs Industry: S09 is good value based on its Price-To-Sales Ratio (1.3x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is S09's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

S09 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: S09 is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst S09 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.38
€11.52
+384.2%
34.6%€19.21€4.80n/a10
Nov ’25€3.36
€10.97
+226.6%
34.6%€18.29€4.57n/a10
Oct ’25€3.06
€10.89
+255.8%
34.6%€18.14€4.54n/a10
Sep ’25€4.06
€10.89
+168.1%
34.6%€18.14€4.54n/a10
Aug ’25€3.62
€11.46
+216.6%
36.2%€18.64€4.66n/a10
Jul ’25€2.66
€11.46
+330.9%
36.2%€18.64€4.66n/a10
Jun ’25€3.98
€11.59
+191.3%
32.0%€18.40€7.36n/a10
May ’25€3.22
€12.07
+275.0%
32.2%€18.74€7.49n/a9
Apr ’25€5.05
€12.72
+151.9%
39.4%€23.08€7.39n/a9
Mar ’25€4.46
€13.48
+202.2%
34.5%€22.98€7.35n/a9
Feb ’25€3.94
€13.48
+242.1%
34.5%€22.98€7.35n/a9
Jan ’25€3.88
€13.45
+246.7%
34.5%€22.93€7.34n/a9
Dec ’24€2.36
€14.52
+515.5%
37.2%€23.90€7.35n/a10
Nov ’24€2.56
€15.84
+518.7%
34.8%€24.38€7.50€3.369
Oct ’24€3.32
€16.25
+389.6%
32.0%€23.81€7.33€3.068
Sep ’24€4.32
€16.25
+276.2%
32.0%€23.81€7.33€4.068
Aug ’24€4.00
€17.19
+329.8%
28.1%€23.84€7.34€3.628
Jul ’24€4.20
€17.19
+309.4%
28.1%€23.84€7.34€2.668
Jun ’24€4.14
€17.48
+322.2%
28.1%€24.24€7.46€3.988
May ’24€4.00
€17.69
+342.1%
29.2%€23.73€7.30€3.228
Apr ’24€4.04
€18.21
+350.7%
28.3%€23.97€7.38€5.058
Mar ’24€5.20
€20.42
+292.7%
23.9%€30.46€13.84€4.468
Feb ’24€6.55
€20.42
+211.7%
23.9%€30.46€13.84€3.948
Jan ’24€7.25
€21.35
+194.5%
25.2%€32.96€14.98€3.888
Dec ’23€7.10
€21.35
+200.7%
25.2%€32.96€14.98€2.368
Nov ’23€7.30
€22.70
+211.0%
26.7%€33.11€15.05€2.568

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.90

7D

3.6%

1Y

75.1%

Perrigo

US$3.8b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$27.00

7D

6.8%

1Y

-3.6%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%